Abstract
Aim:To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients.Patients & methods:The distribution of peripheral blood NK cells of 31 patients was analyzed by flow cytometry.Results:We detected a decrease of NK cells in peripheral blood below normal range after obinutuzumab treatment. During maintenance treatment with subcutaneous rituximab, an NK cell reduction was less pronounced than after intravenous rituximab treatment, despite lymphokine-activated killer cell infusions.Conclusion:After one dose of obinutuzumab, each NK cell in peripheral blood destroys 25 leukemic cells.
Highlights
Author contributions R Garcıa-Munoz, J Feliu, J Anton-Remırez, L Aguinaga, C Panizo and E Domınguez-Garrido contributed to the study design, data analysis, interpretation, and wrote the paper
The monoclonal antibodies or TriKE assumes the function of a general who guides his brave warriors (expansions of LAKs, natural killer (NK) cells or γδ T cells) into battle
Summary
To analyze the effects of subcutaneous or intravenous rituximab + lymphokine-activated killer cells, obinutuzumab or ibrutinib on natural killer (NK) cell levels in chronic lymphocytic leukemia and follicular lymphoma patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
